{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:09:34Z","timestamp":1784822974530,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.7759\/cureus.31022","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:09:46Z","timestamp":1667416186000},"source":"Crossref","is-referenced-by-count":4,"title":["Vitiligo and the Role of Newer Therapeutic Modalities"],"prefix":"10.7759","author":[{"given":"Prathmesh","family":"Nimkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Wanjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist C","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020, 236:571-92. 10.1159\/000506103","journal-title":"Dermatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan A","year":"2011","unstructured":"Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011, 65:473-91. 10.1016\/j.jaad.2010.11.061","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.1370020107","article-title":"Studies on vitiligo. I. Epidemiological profile in Calcutta, India","volume":"2","author":"Das SK","year":"1985","unstructured":"Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B,  Rao DC. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol. 1985, 2:71-8. 10.1002\/gepi.1370020107","journal-title":"Genet Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.32708","article-title":"Vitiligo: compendium of clinico-epidemiological features","volume":"73","author":"Sehgal VN","year":"2007","unstructured":"Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007, 73:149-56. 10.4103\/0378-6323.32708","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2015.56.3.719","article-title":"Prevalence of vitiligo and associated comorbidities in Korea","volume":"56","author":"Lee H","year":"2015","unstructured":"Lee H, Lee MH, Lee DY, et al.. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015, 56:719-25. 10.3349\/ymj.2015.56.3.719","journal-title":"Yonsei Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine K","year":"2012","unstructured":"Ezzedine K, Lim HW, Suzuki T, et al.. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012, 25:E1-13. 10.1111\/j.1755-148X.2012.00997.x","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo M","year":"2015","unstructured":"Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. Nat Rev Dis Primers. 2015, 1:15011. 10.1038\/nrdp.2015.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine K","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015, 386:74-84. 10.1016\/s0140-6736(14)60763-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1993.tb00023.x","article-title":"Review of the etiopathomechanism of vitiligo: a convergence theory","volume":"2","author":"Le Poole IC","year":"1993","unstructured":"Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993, 2:145-53. 10.1111\/j.1600-0625.1993.tb00023.x","journal-title":"Exp Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.02.004","article-title":"Immunopathogenesis of vitiligo","volume":"10","author":"Sandoval-Cruz M","year":"2011","unstructured":"Sandoval-Cruz M, Garc\u00eda-Carrasco M, S\u00e1nchez-Porras R, Mendoza-Pinto C, Jim\u00e9nez-Hern\u00e1ndez M, Mungu\u00eda-Realpozo P, Ruiz-Arg\u00fcelles A. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011, 10:762-5. 10.1016\/j.autrev.2011.02.004","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.10.010","article-title":"Innate immune mechanisms in vitiligo: danger from within","volume":"25","author":"Richmond JM","year":"2013","unstructured":"Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013, 25:676-82. 10.1016\/j.coi.2013.10.010","journal-title":"Curr Opin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.004","article-title":"The genetic basis of vitiligo","volume":"141","author":"Spritz RA","year":"2021","unstructured":"Spritz RA, Santorico SA. The genetic basis of vitiligo. J Invest Dermatol. 2021, 141:265-73. 10.1016\/j.jid.2020.06.004","journal-title":"J Invest Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.09.003","article-title":"Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?","volume":"81","author":"Xie H","year":"2016","unstructured":"Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, Gao T. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?. J Dermatol Sci. 2016, 81:3-9. 10.1016\/j.jdermsci.2015.09.003","journal-title":"J Dermatol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00666_1.x","article-title":"Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?","volume":"17","author":"Ralf Paus L","year":"2008","unstructured":"Ralf Paus L, Schallreuter KU, Bahadoran P, et al.. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. Exp Dermatol. 2008, 17:139-40. 10.1111\/j.1600-0625.2007.00666_1.x","journal-title":"Exp Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.16","article-title":"Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy","volume":"131","author":"van den Boorn JG","year":"2011","unstructured":"van den Boorn JG, Picavet DI, van Swieten PF, et al.. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011, 131:1240-51. 10.1038\/jid.2011.16","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051040","article-title":"Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin","volume":"7","author":"Yu R","year":"2012","unstructured":"Yu R, Broady R, Huang Y, et al.. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One. 2012, 7:e51040. 10.1371\/journal.pone.0051040","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23653.x","article-title":"4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo","volume":"124","author":"Kroll TM","year":"2005","unstructured":"Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, Mestril R, Caroline Le Poole I. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol. 2005, 124:798-806. 10.1111\/j.0022-202X.2005.23653.x","journal-title":"J Invest Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.181","article-title":"Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8","volume":"132","author":"Toosi S","year":"2012","unstructured":"Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012, 132:2601-9. 10.1038\/jid.2012.181","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12183","article-title":"A central role for inducible heat-shock protein 70 in autoimmune vitiligo","volume":"22","author":"Mosenson JA","year":"2013","unstructured":"Mosenson JA, Eby JM, Hernandez C, Le Poole IC. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol. 2013, 22:566-9. 10.1111\/exd.12183","journal-title":"Exp Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine","volume":"138","author":"Henning SW","year":"2018","unstructured":"Henning SW, Fernandez MF, Mahon JP, et al.. HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine. J Invest Dermatol. 2018, 138:2531-9. 10.1016\/j.jid.2018.06.186","journal-title":"J Invest Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.003","article-title":"Treatment with modified heat shock protein repigments vitiligo lesions in Sinclair swine","volume":"138","author":"Frisoli ML","year":"2018","unstructured":"Frisoli ML, Harris JE. Treatment with modified heat shock protein repigments vitiligo lesions in Sinclair swine. J Invest Dermatol. 2018, 138:2505-6. 10.1016\/j.jid.2018.08.003","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000375","article-title":"Understanding autoimmunity of vitiligo and alopecia areata","volume":"28","author":"Rork JF","year":"2016","unstructured":"Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016, 28:463-9. 10.1097\/MOP.0000000000000375","journal-title":"Curr Opin Pediatr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi M","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, et al.. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014, 6:223ra23. 10.1126\/scitranslmed.3007811","journal-title":"Sci Transl Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang XX","year":"2016","unstructured":"Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016, 174:1318-26. 10.1111\/bjd.14416","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8\u207a T-cell accumulation in the skin","volume":"132","author":"Harris JE","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8\u207a T-cell accumulation in the skin. J Invest Dermatol. 2012, 132:1869-76. 10.1038\/jid.2011.463","journal-title":"J Invest Dermatol"},{"key":"ref26","article-title":"Davidson\u2019s Principles and Practice of Medicine","year":"2022","unstructured":"Davidson\u2019s Principles and Practice of Medicine. Ralston SH, Penman I, Strachan M, Hobson R (ed). Elsevier , London; 2022."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(86)70160-6","article-title":"Psychosocial effect of vitiligo: a comparison of vitiligo patients with \u201cnormal\u201d control subjects, with psoriasis patients, and with patients with other pigmentary disorders","volume":"15","author":"Porter JR","year":"1986","unstructured":"Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with \u201cnormal\u201d control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol. 1986, 15:220-224. 10.1016\/s0190-9622(86)70160-6","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0163-8343(79)90081-1","article-title":"Psychological reaction to chronic skin disorders: a study of patients with vitiligo","volume":"1","author":"Porter J","year":"1979","unstructured":"Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979, 1:73-7. 10.1016\/0163-8343(79)90081-1","journal-title":"Gen Hosp Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.116737","article-title":"The psychosocial impact of vitiligo in Indian patients","volume":"79","author":"Pahwa P","year":"2013","unstructured":"Pahwa P, Mehta M, Khaitan BK, Sharma VK, Ramam M. The psychosocial impact of vitiligo in Indian patients. Indian J Dermatol Venereol Leprol. 2013, 79:679-85. 10.4103\/0378-6323.116737","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1348\/000711299160077","article-title":"Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy","volume":"72 ( Pt 3)","author":"Papadopoulos L","year":"1999","unstructured":"Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol. 1999, 72 ( Pt 3):385-96. 10.1348\/000711299160077","journal-title":"Br J Med Psychol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.039","article-title":"Vitiligo is not a cosmetic disease","volume":"73","author":"Ezzedine K","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, Pandya AG. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015, 73:883-5. 10.1016\/j.jaad.2015.07.039","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues M","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017, 77:17-29. 10.1016\/j.jaad.2016.11.010","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12399","article-title":"Interventions for vitiligo","volume":"316","author":"Ezzedine K","year":"2016","unstructured":"Ezzedine K, Whitton M, Pinart M. Interventions for vitiligo. JAMA. 2016, 316:1708-9. 10.1001\/jama.2016.12399","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02278.x","article-title":"Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy","volume":"21","author":"Brazzelli V","year":"2007","unstructured":"Brazzelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol. 2007, 21:1369-74. 10.1111\/j.1468-3083.2007.02278.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb A","year":"2013","unstructured":"Taieb A, Alomar A, B\u00f6hm M, et al.. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013, 168:5-19. 10.1111\/j.1365-2133.2012.11197.x","journal-title":"Br J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12295","article-title":"Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis","volume":"29","author":"Dang YP","year":"2016","unstructured":"Dang YP, Li Q, Shi F, Yuan XY, Liu W. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016, 29:126-33. 10.1111\/dth.12295","journal-title":"Dermatol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12277","article-title":"Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis","volume":"33","author":"Li R","year":"2017","unstructured":"Li R, Qiao M, Wang X, Zhao X, Sun Q. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. Photodermatol Photoimmunol Photomed. 2017, 33:22-31. 10.1111\/phpp.12277","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae JM","year":"2017","unstructured":"Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017, 153:666-74. 10.1001\/jamadermatol.2017.0002","journal-title":"JAMA Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12532","article-title":"Surgical interventions for vitiligo: an evidence-based review","volume":"169 Suppl 3","author":"Mulekar SV","year":"2013","unstructured":"Mulekar SV, Isedeh P. Surgical interventions for vitiligo: an evidence-based review. Br J Dermatol. 2013, 169 Suppl 3:57-66. 10.1111\/bjd.12532","journal-title":"Br J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19084812","article-title":"Surgical Treatment of Vitiligo","volume":"19","author":"Fr\u0105czek A","year":"2022","unstructured":"Fr\u0105czek A, Kasprowicz-Furma\u0144czyk M, Placek W, Owczarczyk-Saczonek A. Surgical Treatment of Vitiligo. Int J Environ Res Public Health. 2022, 19:10.3390\/ijerph19084812","journal-title":"Int J Environ Res Public Health"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4103\/amhs.amhs_50_20","article-title":"Vitiligo with special emphasis on vitiligo surgery","volume":"8","author":"Ashwini PK","year":"2020","unstructured":"Ashwini PK, Sushmitha DJ, Veeranna S. Vitiligo with special emphasis on vitiligo surgery. Arch Med Health Sci. 2020, 8:140-6. 10.4103\/amhs.amhs_50_20","journal-title":"Arch Med Health Sci"},{"key":"ref42","article-title":"Advances in vitiligo: an update on medical and surgical treatments","volume":"10","author":"Dillon AB","year":"2017","unstructured":"Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in vitiligo: an update on medical and surgical treatments. J Clin Aesthet Dermatol. 2017, 10:15-28.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.53196","article-title":"Tissue grafts in vitiligo surgery - past, present, and future","volume":"54","author":"Khunger N","year":"2009","unstructured":"Khunger N, Kathuria SD, Ramesh V. Tissue grafts in vitiligo surgery - past, present, and future. Indian J Dermatol. 2009, 54:150-8. 10.4103\/0019-5154.53196","journal-title":"Indian J Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.21608\/jram.2020.44431.1086","article-title":"Updates in surgical treatment of vitiligo","volume":"2","author":"Gamal A","year":"2021","unstructured":"Gamal A, El-Barbary R, Moftah N. Updates in surgical treatment of vitiligo. J Adv Med Med Res. 2021, 2:118-27. 10.21608\/jram.2020.44431.1086","journal-title":"J Adv Med Med Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.5114\/dr.2019.83440","article-title":"Vitiligo. Diagnostic and therapeutic recommendations of the Polish Dermatological Society","volume":"106","author":"Czajkowski R","year":"2019","unstructured":"Czajkowski R, Placek W, Flisiak I, et al.. Vitiligo. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegl Dermatol. 2019, 106:1-15. 10.5114\/dr.2019.83440","journal-title":"Przegl Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow BG","year":"2015","unstructured":"Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015, 151:1110-2. 10.1001\/jamadermatol.2015.1520","journal-title":"JAMA Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris JE","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, et al.. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016, 74:370-1. 10.1016\/j.jaad.2015.09.073","journal-title":"J Am Acad Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi F","year":"2021","unstructured":"Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021, 12:790125. 10.3389\/fimmu.2021.790125","journal-title":"Front Immunol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan DP","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021, 398:803-16. 10.1016\/s0140-6736(21)00438-4","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing L","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al.. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014, 20:1043-9. 10.1038\/nm.3645","journal-title":"Nat Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine A","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, et al.. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013, 122:1192-202. 10.1182\/blood-2013-03-484642","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease P","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al.. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017, 377:1537-50. 10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1159\/000514535","article-title":"Biological therapies for atopic dermatitis: a systematic review","volume":"237","author":"Zhou S","year":"2021","unstructured":"Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: a systematic review. Dermatology. 2021, 237:542-52. 10.1159\/000514535","journal-title":"Dermatology"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu LY","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017, 77:675-682.e1. 10.1016\/j.jaad.2017.05.043","journal-title":"J Am Acad Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib","volume":"61","author":"Mumford BP","year":"2020","unstructured":"Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib. Australas J Dermatol. 2020, 61:374-6. 10.1111\/ajd.13348","journal-title":"Australas J Dermatol"},{"key":"ref56","article-title":"Cyclophosphamide and vitiligo","volume":"18","author":"Gokhale BB","year":"1979","unstructured":"Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol. 1979, 18:92.","journal-title":"Int J Dermatol"},{"key":"ref57","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 Agents","volume":"11","author":"Alghamdi KM","year":"2012","unstructured":"Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-\u03b1 Agents. J Drugs Dermatol. 2012, 11:534-9.","journal-title":"J Drugs Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos D","year":"2007","unstructured":"Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D. Etanercept in the treatment of vitiligo. Dermatology. 2007, 215:84-5. 10.1159\/000102044","journal-title":"Dermatology"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14286","article-title":"Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial","volume":"58","author":"Parambath N","year":"2019","unstructured":"Parambath N, Sharma VK, Parihar AS, Sahni K, Gupta S. Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial. Int J Dermatol. 2019, 58:472-6. 10.1111\/ijd.14286","journal-title":"Int J Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12194","article-title":"The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study","volume":"15","author":"Ibrahim ZA","year":"2016","unstructured":"Ibrahim ZA, El-Ashmawy AA, El-Tatawy RA, Sallam FA. The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study. J Cosmet Dermatol. 2016, 15:108-16. 10.1111\/jocd.12194","journal-title":"J Cosmet Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4103\/JCAS.JCAS_68_17","article-title":"Overview of medical therapies and phototherapy in vitiligo based on their pathogenetic action and the role of platelet-rich plasma","volume":"11","author":"Sardana K","year":"2018","unstructured":"Sardana K, Verma G. Overview of medical therapies and phototherapy in vitiligo based on their pathogenetic action and the role of platelet-rich plasma. J Cutan Aesthet Surg. 2018, 11:167-8. 10.4103\/JCAS.JCAS_68_17","journal-title":"J Cutan Aesthet Surg"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2019.32.58.16779","article-title":"Vitiligo and Koebner phenomenon following platelet-rich plasma injections (Article in French)","volume":"32","author":"Ejjiyar M","year":"2019","unstructured":"Ejjiyar M, Sahibi M, El Gueouatri M, et al.. Vitiligo and Koebner phenomenon following platelet-rich plasma injections (Article in French). Pan Afr Med J. 2019, 32:58. 10.11604\/pamj.2019.32.58.16779","journal-title":"Pan Afr Med J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/116656-vitiligo-and-the-role-of-newer-therapeutic-modalities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:47Z","timestamp":1707508067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/116656-vitiligo-and-the-role-of-newer-therapeutic-modalities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.31022","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}